- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Patent holdings for IPC class C07K 16/28
Total number of patents in this class: 53405
10-year publication summary
|
2997
|
3470
|
4164
|
4539
|
4863
|
4974
|
4860
|
5299
|
4922
|
3174
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4786 |
1153 |
| Genentech, Inc. | 4114 |
823 |
| Hoffmann-La Roche Inc. | 3818 |
662 |
| The Regents of the University of California | 20815 |
600 |
| Amgen Inc. | 4440 |
600 |
| F. Hoffmann-La Roche AG | 7808 |
582 |
| Bristol-myers Squibb Company | 4757 |
577 |
| Immatics Biotechnologies GmbH | 1127 |
567 |
| Novartis AG | 10173 |
556 |
| Janssen Biotech, Inc. | 1782 |
537 |
| Memorial Sloan-Kettering Cancer Center | 2051 |
442 |
| Chugai Seiyaku Kabushiki Kaisha | 1423 |
416 |
| The Trustees of the University of Pennsylvania | 4423 |
364 |
| The Board of Trustees of the Leland Stanford Junior University | 6687 |
338 |
| Board of Regents, The University of Texas System | 6141 |
324 |
| Genmab A/S | 477 |
313 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3330 |
311 |
| Xencor, Inc. | 411 |
298 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
288 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3010 |
274 |
| Other owners | 43380 |